PROBLEM

Lacking data and targets?

The industry’s biggest challenge is that it is difficult to obtain enough usable and actionable data that results in novel drug targets. This makes even the best organisations fall behind the competition.

10+
Years

Drug discovery is a long process, often taking over 10 years to find the right targets

Unusable
Data

Data is not standardised and is difficult to access

Limited
Insights

Analysis is often limited to pre-configured tools

Unverifiable
Insights

Difficult to verify targets without clinical records

Only with the right data, you avoid going from…

Only with the right data, you avoid going from…

SOLUTION

Connect to the world’s unused data to obtain novel therapeutic insights
We believe that all data that can be used to cure diseases, should be used.
150+​

Biobanks and Population Genomics initiatives making their biomedical data available

10M+​

Datasets within our network,
ranging from cancer to rare diseases

100M+

Real World Evidence data points
in our real time learning knowledge graph

TESTIMONIAL

This platform will play an important part of Boehringer Ingelheim’s broader strategy to capture translational disease insights from large external healthcare biobanks and ultimately to accelerate the development of innovative medicines.
person-2
Dr. Jan Nygaard Jensen
SVP & Global Head of Computational Biology & Digital Sciences
Get started

1

Book a Demo

Our experts are on hand to show you how leaders find the right data.

2

Build Your Data Strategy

Co-develop a plan to find all data you need and extract the right insights.

3

Become a Leader

Connect your organisation to the right data for disease insights.
Book a demo

Press Release

Boehringer Ingelheim partners with Lifebit to detect outbreaks

Read more

White Paper

Disease surveillance with Lifebit REAL - Tracking tomorrow’s diseases today

Read more
Lifebit Real